ReviewInternational journal of molecular sciences2021
Current and Future Development in Lung Cancer Diagnosis.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06473870 (Understanding Lung Cancer Related Risk Factors and Their Impact), which is not on this map. Cited by 470 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Understanding Lung Cancer Related Risk Factors and Their Impact
Who cites it
470 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Mitochondrial DNA Copy Numbers and Lung Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Salivary Extracellular Vesicles in Detection of Cancers Other than Head and Neck: A Systematic Review.Cells · 2025Pooled it
- The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.PloS one · 2025Pooled it
- Trial
- Recruitment preferences for lung cancer screening among 4-IN-THE-LUNG-RUN participants.BMC public health · 2026Trial
- Modified Borg Scale (mBorg), the Numerical Rating Scale (NRS), and the Dyspnea- 12 Scale (D- 12): cross-scale comparison assessing the development of dyspnea in early-stage lung cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics.Genes & diseases · 2026Review
- Vismodegib-loaded ufasomes inhaler for treatment of non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer.Radiology and oncology · 2026Article
- Impact of surgical approaches on prognosis in elderly patients with T4N0M0 non-small cell lung cancer: a competing risk analysis based on the SEER database.Journal of thoracic disease · 2026Article
- mCancer science · 2026Article
- Label-free Raman spectroscopic imaging enables high-content molecular phenotyping of respiratory diseases from bronchoalveolar lavage fluid.Journal of translational medicine · 2026Article
- Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade.Cancer immunology research · 2026Article
- Cepharanthine suppresses lung adenocarcinoma through targeting glutathione peroxidase 4.Oncology letters · 2026Article
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Mechanisms of LARP7 in regulating the progression of non-small cell lung cancer.Journal of thoracic disease · 2026Article
- Engineered Yolk-Shell Nanocarriers for Biphasic Release and Efficient Codelivery of Chemotherapy Drugs in Lung Cancer Cells.ACS omega · 2026Article
- Insulinoma-associated Protein-1 as a Biomarker for Diagnosis of Small Cell Lung Cancer: A Meta-analysis.Pakistan journal of medical sciences · 2026Review
- GAN-generated target reconstruction CT radiomics for prediction of the novel IASLC grading of pulmonary adenocarcinoma.Journal of thoracic disease · 2026Article
410 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.